17291-90-6

Basic information

• Product Name: 2,6-Difluorophenethylamine97%
• Synonyms: 2,6-Difluorophenethylamine97%;2,6-DIFLUOROPHENETHYLAMINE 97%;BenzeneethanaMine, 2,6-difluoro-;2,6-Difluorophenethylamine
• CAS NO: 17291-90-6
• Molecular Formula: C₈H₉F₂N
• Molecular Weight: 157.1605664
• Mol File: 17291-90-6.mol

Chemical Properties

• Boiling Point: 193℃
• Flash Point: 83℃
• Appearance: /
• Density: 1.169
• PKA: 9.04±0.10(Predicted)
• CAS DataBase Reference: 2,6-Difluorophenethylamine97%(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Difluorophenethylamine97%(17291-90-6)
• EPA Substance Registry System: 2,6-Difluorophenethylamine97%(17291-90-6)

Safety Data

• Hazardous Substances Data: 17291-90-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Difluorophenethylamine97% is used as a chemical intermediate for the synthesis of new and more effective drugs. Its fluorination enhances bioactivity and stability, making it a valuable component in the development of pharmaceutical products.
Used in Agrochemical Industry:
2,6-Difluorophenethylamine97% is used as a chemical intermediate in the production of pesticides. Its fluorination contributes to the effectiveness and stability of these agrochemical products, improving their performance in agricultural applications.
Used in Performance Materials Industry:
2,6-Difluorophenethylamine97% is used as a chemical intermediate in the development of specialized industrial materials. Its fluorination provides enhanced properties, such as increased bioactivity and stability, which are beneficial for the creation of high-performance materials.

Upstream product

• 20263-81-4 3,5-difluoro-β-nitrostyrene 
• 654-01-3 (2,6-difluorophenyl)acetonitrile 

Downstream Products

• 149487-86-5 1-[2-(2,6-Difluoro-phenyl)-ethyl]-3-(4-ethyl-thiazol-2-yl)-thiourea 
• 149488-58-4 1-(4-Cyano-thiazol-2-yl)-3-[2-(2,6-difluoro-phenyl)-ethyl]-thiourea 
• 149487-88-7 N-(thioimidazolyl)-2-(2,6-difluorophenyl)ethylamine 
• 149488-13-1 1-(5-Bromo-pyridin-2-yl)-3-[2-(2,6-difluoro-phenyl)-ethyl]-thiourea 
• 149487-94-5 1-[2-(2,6-Difluoro-phenyl)-ethyl]-3-(5-methyl-pyridin-2-yl)-thiourea 
• 149488-22-2 N-(2-(2,6-difluorophenyl)ethyl)-N'-(2-pyrazinyl)-thiourea 

Relevant articles and documents

DOLASTATIN-10 DERIVATIVE, METHOD OF PRODUCING SAME AND ANTICANCER DRUG COMPOSITION CONTAINING SAME

The present invention provides a dolastatin-10 derivative having excellent anticancer activity, a method of producing the same and anticancer drug composition containing the same as an active ingredient.

N-arylalkyl-N-heteroarylurea and guandine compounds and methods of treating HIV infection

A method for treating HIV which comprises a compound of the formula STR1 wherein A is STR2 and Zi is O, Se, NRa or C(Ra)2, and Zii is --O or (=O)2 ; wherein R1, R2, R3, and R4 are as defined in the specification.

Method for inhibition of HIV related viruses

Treatment of AIDS, inhibition of the replication of HIV and related viruses thereof, and formulations using thiourea derivative compounds or salts thereof is disclosed. Also disclosed are novel thiourea derivative compounds.

Phenethylthiazolylthiourea (PETT) compounds as a new class of HIV-1 reverse transcriptase inhibitors. 2. Synthesis and further structure-activity relationship studies of PETT analogs

Phenylethylthiazolylthiourea (PETT) derivatives have been identified as a new series of nonnucleoside inhibitors of HIV-1 RT. Structure-activity relationship studies of this class of compounds resulted in the identification of N-[2-(2-pyridyl)ethyl]-N'-[2-(5-bromopyridyl)]-thiourea hydrochloride (trovirdine; LY300046.HCl) as a highly potent anti-HIV-1 agent. Trovirdine is currently in phase one clinical trials for potential use in the treatment of AIDS. Extension of these structure-activity relationship studies to identify additional compounds in this series with improved properties is ongoing. A part of this work is described here. Replacement of the two aromatic moleties of the PETT compounds by various substituted or unsubstituted heteroaromatic rings was investigated. In addition, the effects of multiple substitution in the phenyl ring were also studied. The antiviral activities were determined on wild-type and constructed mutants of HIV-1 RT and on wild-type HIV-1 and mutant viruses derived thereof, Ile100 and Cys181, in cell culture assays. Some selected compounds were determined on double- mutant viruses, HIV-1 (Ile100/Asn103) and HIV-1 (Ile100/Cys181). A number of highly potent analogs were synthesized. These compounds displayed IC50's against wild-type RT between 0.6 and 5 nM. In cell culture, these agents inhibited wild-type HIV-1 with ED50's between I and 5 nM in MT-4 cells. In addition, these derivatives inhibited mutant HIV-1 RT (Ile 100) with IC50's between 20 and 50 nM and mutant HIV-1 RT (Cys 181) with IC50's between 4 and 10 nM, and in cell culture they inhibited mutant HIV-1 (Ile100) with ED50's between 9 and 100 nM and mutant HIV-1 (Cys181) with ED50's between 3 and 20 nM.

Phenethylthiazolethiourea (PETT) compounds, a new class of HIV-1 reverse transcriptase inhibitors. 1. Synthesis and basic structure-activity relationship studies of PETT analogs

A novel series of potent specific HIV-1 inhibitory compounds is described. The lead compound in the series, N-(2-phenethyl)-N'-(2-thiazolyl)thiourea (1), inhibits HIV-1 RT using rCdG as the template with an IC50 of 0.9 μM. In MT-4 cells, compound 1 inhibits HIV-1 with an ED50 of 1.3 μM. The 50% cytotoxic dose in cell culture is >380 μM. The chemical structure-activity relationship (SAR) was developed by notionally dividing the lead compound in four quadrants. The SAR strategy had two phases. The first phase involved optimization of antiviral activity through independent variation of quadrants 1-4. The second phase involved the preparation of hybrid structures combining the best of these substituents. Further SAR studies and pharmacokinetic considerations led to the identification of N-(2-pyridyl)-N'-(5-bromo-2- pyridyl)-thiourea (62; LY300046 · HCl) as a candidate for clinical evaluation. LY300046 · HCl inhibits HIV-1 RT with an IC50 of 15 nM and in cell culture has an ED50 of 20 nM.